sacituzumab govitecan
gilead sciences
['ascent', 'bcsm', '1071', 'tnbc', 'sacituzumab']
#asco22 poster 1071
final analysis from #ascent significant in median pfs (hr 0.39) and os (hr 0.48) with #sacituzumabgovitecan vs single-agent chemotherapy with improved hrqol outcomes #bcsm #tnbc 
Medonc at dpt of general medical oncology @UZleuven ????Knight to improve outcome of breast cancer pts ???? #TNBC #BCY #HereditaryCancerSyndromes